Freedom And Capital Drive Intarcia Down Independent Path

With a lucrative and unique royalty financing deal and positive first results from its global Phase III diabetes study, Intarcia has emerged as one of the biotech industry’s most valuable private companies and is in position to control its own destiny. It just may disrupt the type 2 diabetes market in the process.